Viral Vectors & Plasmid DNA Manufacturing Market Size to Surpass USD 5,989.21 Million by 2032

The global viral vectors & plasmid DNA manufacturing market size reached USD 1,237.45 million in 2022 and is expected to surpass around USD 5,989.21 million by 2032, growing at a healthy CAGR of 16.8% between 2023 to 2032.

The global viral vectors & plasmid DNA manufacturing market size accounted for USD 1,444.54 million in 2023 and is expected to reach around USD 3,705.98 million by 2029. North America has held the maximum market share in 2022.

Market Overview

Viral vectors & plasmid DNA manufacturing market refers to the segment of the biopharmaceutical industry that focuses on the production and manufacturing of viral vectors and plasmid DNA. These are essential components in the field of gene and cell therapy, playing a crucial role in the development and production of advanced therapeutics. The viral vectors & plasmid DNA manufacturing market is thriving due to a rise in target disorders and the effectiveness of viral vectors in gene therapy delivery. Ongoing research coupled with sufficient funding for gene therapy advancements, further fuels this growth. Despite the complexity of viral vectors, the industry relies on multifaceted methods to ensure product quality until revolutionary technologies enable streamlined analysis integration.

Download the Sample Copy of Report@ https://www.precedenceresearch.com/sample/1012

Rising number of strategic partnerships and collaborations among industry players underscores the surging interest in vector manufacturing. These collaborations serve diverse purposes, from enhancing vector promoters’ production to developing/acquiring manufacturing facilities and engaging in out/in licensing of vector manufacturing technology. Joining forces in this dynamic landscape is crucial for driving innovation and advancing the field collectively.

Key Insights:

• In viral vectors & plasmid DNA manufacturing market the AAV segment is growing at the highest rate.
• In the viral vectors & plasmid DNA manufacturing market, the downstream processing sector exhibits a leading position.
• Throughout the forecast period, the cancer sector is anticipated to continue to hold a dominant position in the market.

Growth Factors:

• Viral and non-viral vectors are vital for innovative medicines, with optimized production strategies crucial for regulatory compliance. Streamlined vector manufacturing accelerates healing development from clinical stages to market approval. Despite being complex, it is critical in producing gene therapies and vaccines. Significant improvements have been witnessed with the introduction of new protocols. Embracing these advancements ensures high-quality vector production for breakthroughs in medicine.
• The demand for plasmid DNA is steadily rising with the growth of gene therapy development. Plasmid DNA is essential for producing crucial viral vector platforms like AAV and lentivirus. With an increase in genetic disorders and life-threatening conditions such as heart diseases, AIDS, and cystic fibrosis, gene therapy using viral vectors offers a potential complete cure rather than just symptom relief.
• Clinical studies in viral vector and plasmid DNA manufacturing highlight the promising potential of gene therapy in addressing significant medical needs, providing hope for transformative treatments.

• Furthermore, the untapped regions’ increasing market potential and the rising interest in synthetic genes create profitable prospects for visionary industry players. Industry manufacturers play a pivotal role in leading the way through a transformative era, where innovations have the potential to reshape the gene therapy landscape and address the ever-changing healthcare needs.
  

You can place an order or ask any questions, please feel free to contact at

sales@precedenceresearch.com | +1 650 460 3308

Report Highlights

• Pharmaceutical and biopharmaceutical companies are expected to collect major share of the global vector market. This is because of the effective launch of viral vector gene therapies and a vigorous pipeline of such therapies that helps growth of pharmaceutical and biopharmaceutical companies during near future.

• Presently, around two-thirds of the gene therapy research is dedicated to oncology. These different facts have backed the governance of cancer segment over other disease segments

• Extensive progress made in gene and cell therapy research since the early 1970s and 1980s has accelerated the adoption rate of plasmids and viral vectors for their use in these modern therapies

• Presently, U.S. and Europe have seemed as vector manufacturing centers despite of the fact that the first 3 gene therapy candidates were granted in Asian countries

Regional Stance

The FDA’s recent approval of cutting-edge treatments like Kymriah (tisagenlecleucel) and Yescarta supports the significant investment in the US market for vector production. Furthermore, it is anticipated that the industrialization of gene therapy manufacturing and clinical transformation will lead to significant advancements in a number of Asian countries.

Many international corporations are collaborating with Asian-based businesses in an effort to accelerate vector manufacturing in Asia Pacific. Currently, despite the fact that the first three gene therapy candidates (Oncorine®, Gendicine®, and Rexin-G®) were approved in Asian nations, the United States and Europe have emerged as major centres for the production of vectors. This success can be attributed to the large number of long-lasting clinical trials conducted in these well-established areas. North America is home to over 68% of all active international clinical trials for gene treatments. About 21% of trials are currently underway in Europe, which is the second-largest market for trials.

Ask Here for Customization@ https://www.precedenceresearch.com/customization/1012

Viral Vectors & Plasmid DNA Manufacturing Market Scope

Market Potential:

The rise of mRNA therapeutics, exemplified by the success of COVID-19 vaccines, has generated significant interest in nucleic acid-based therapies. This includes the use of viral vectors and plasmid DNA, further amplifying the demand for manufacturing capacities. As gene therapies advance from experimental phases to clinical use, there’s a heightened demand for trustworthy, top-tier vectors and DNA constructs, underscoring the market’s pivotal role in advancing transformative medical solutions.

The North American viral vector and plasmid DNA manufacturing market is on a robust growth path, owing to a well-established research infrastructure, a thriving pharmaceutical and biotech industry, and strong government support for life science research. Technological advancements and collaborative initiatives further fuel this growth. For instance, the region grapples with a substantial burden of chronic diseases like cancer and cardiovascular issues. This escalating health challenge propels the demand for viral vector and plasmid DNA manufacturing in research and crucial clinical applications. Investing in this market is not just about growth but addressing pressing health needs through cutting-edge solutions.

Related Reports:

• DNA Diagnostics Market: The global DNA diagnostics market size was reached at USD 12.46 billion in 2022 and is expected to hit around USD 20.1 billion by 2032, poised to grow at a CAGR of 4.9% from 2023 to 2032.
  
• DNA Synthesis Market: The global DNA synthesis market size accounted for USD 3.50 billion in 2022, and it is projected to be worth around USD 20.87 billion by 2032, with a compound annual growth rate (CAGR) of 19.6% from 2023 to 2032.
  
• Gene Expression Market: The global gene expression market size surpassed USD 12.19 billion in 2022 and is expected to hit around USD 32.85 billion by 2032, poised to grow at a CAGR of 10.42% during the forecast period from 2023 to 2032.

Industry Spotlight:

• In August 2022, MERCK KGaA introduced the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform, providing a comprehensive viral vector manufacturing solution, including AAV and Lentiviral vectors. In May 2022, Catalent Inc. launched the UpTempo Virtuoso platform process for developing and manufacturing adeno-associated viral (AAV) vectors.
• Reliable supply sources are crucial for meeting the high demand for plasmid DNA (pDNA). In a GEN webinar on March 30, 2023, experts discussed the challenges arising from the growing adoption of advanced therapies using pDNA. The increased demand for pDNA, essential for manufacturing viral vectors, mRNA, and other applications, poses challenges for specialist manufacturers to keep up with supply requirements. The current scenario often necessitates booking manufacturing well in advance, and insufficient pDNA supplies can lead to costly regulatory delays in therapeutic programs.

Company Synopsis:

Novasep

Novasep is a top service provider for molecule production and purification in the life science industries. They excel in specialized technologies and dedicated teams. After the April 2022 merger of Novasep and PharmaZell Group, the Farmabios, Novasep, and PharmaZell brands are now unified under a single name. This merger combines companies with a shared history of high quality, reliability and a complementary set of differentiated technologies.

Aldevron

Aldevron is a top manufacturing partner that supplies essential nucleic acids and proteins for gene and cell therapies, gene editing technologies, and DNA and RNA vaccines. In September 2023, IDT and Aldevron collaborated to advance global CRISPR research to provide essential solutions for translational medicine. Sandy Ottensmann, VP/GM at IDT, emphasizes the shared commitment to accelerating CRISPR research and enhancing value for the entire CRISPR community.

Their joint efforts aim to expand access to top-tier gene editing reagents and tools, facilitating swift innovation and translation of research breakthroughs into potentially life-saving treatments. This partnership reflects a dedication to advancing genomic medicine and making significant contributions to the future of healthcare.

Oxford Biomedica plc

Partnering with leading pharmaceutical and biotechnology firms, the Company provides expertise in developing and manufacturing viral vectors, encompassing lentivirus, adeno-associated virus (AAV), and adenoviral vectors. In May 2023, Oxford Biomedica plc (LSE: OXB) introduced its latest innovation, TetraVectaTM, a 4th generation lentiviral vector delivery system. Developed in-house, this state-of-the-art technology enhances lentiviral vectors’ quality, potency, and packaging capacity. TetraVectaTM also incorporates new safety features, further strengthening Oxford Biomedica’s client offerings and its leading LentiVector® platform.

You can place an order or ask any questions, please feel free to contact at

sales@precedenceresearch.com | +1 650 460 3308

Market Key Players:

• Novasep
• Aldevron
• MerckWaismanBiomanufacturing
• Creative Biogene
• The Cell and Gene Therapy Catapult
• Cobra Biologics
• uniQure N.V.
• Addgene
• FUJIFILM Holdings Corporation
• Oxford Biomedicaplc
• Takara Bio Inc.

Market Segmentation

By Vector Type

• Adenovirus
• Plasmid DNA
• Lentivirus
• Retrovirus
• AAV
• Others
  

By Application

• Gene Therapy
• Antisense &RNAi
• Cell Therapy
• Vaccinology
  

By Workflow

• Upstream Processing
  • Vector Recovery/Harvesting
  • Vector Amplification & Expansion
• Downstream Processing
  • Fill-finish
  • Purification
    

By End-User

• Biopharmaceutical and Pharmaceutical Companies
• Research Institutes
  

By Disease

• Genetic Disorders
• Cancer
• Infectious Diseases
• Others
  

By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Browse Table of Contents: https://www.precedenceresearch.com/table-of-content/1012

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Immediate Delivery Available | Buy This Premium Research Report@

https://www.precedenceresearch.com/checkout/3410

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

About Us

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Our Blogs:

https://www.towardshealthcare.com

https://www.towardspackaging.com

For Latest Update Follow Us:

Linkedin | Facebook | Twitter